Daniel A. Pryma

8.3k citations

139 papers · 3.7k indexed · h-index 34

Impact in

Radiology, Nuclear Medicine and Imaging top 1%
- Medical Imaging Techniques and Applications
- Radiopharmaceutical Chemistry and Applications
- Radiomics and Machine Learning in Medical Imaging
Oncology top 2%
- Lung Cancer Research Studies

Papers in

Radiology, Nuclear Medicine and Imaging 62
- Medical Imaging Techniques and Applications 29
- Radiopharmaceutical Chemistry and Applications 27
- Radiomics and Machine Learning in Medical Imaging 21
Cancer Research 26
- Cancer, Hypoxia, and Metabolism 15

Co-authors: David A. Mankoff Michael D. Farwell Chaitanya Divgi Steven M. Larson Amy S. Clark Mithat Gönen Mehran Makvandi Robert H. Mach
Journals: Journal of Nuclear Medicine (25 papers)Journal of Clinical Oncology (10 papers)International Journal of Radiation Oncology*Biology*Physics (7 papers)Cancer Research (5 papers)Nuclear Medicine and Biology (4 papers)
Partner nations: United States Switzerland Netherlands

In The Last Decade

Daniel A. Pryma

133 papers receiving 3.6k citations

Peers

Countries citing papers authored by Daniel A. Pryma

Since Specialization

Citations

This map shows the geographic impact of Daniel A. Pryma's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel A. Pryma with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel A. Pryma more than expected).

Fields of papers citing papers by Daniel A. Pryma

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel A. Pryma. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel A. Pryma. The network helps show where Daniel A. Pryma may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Daniel A. Pryma, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Daniel A. Pryma Line = papers co-authored together Daniel A. Pryma links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Relationship of Ketosis With Myocardial Glucose Uptake Among Patients Undergoing FDG PET/CT for Evaluation of Cardiac Sarcoidosis Circulation Cardiovascular Imaging ·Mahesh Vidula, Senthil Selvaraj, Chaitanya Rojulpote, 宗徳高岡, Wumesh KC, Konstantinos Astrapellos, L.Ya Zakstelskaya, Caitlin B. Clancy, Milton D. Rossman, Lee R. Goldberg, Michael D. Farwell, Daniel A. Pryma, Paco E. Bravo	2024	3
2	Coronary Microvascular Dysfunction in Men with Prostate Cancer Receiving Androgen-Deprivation Therapy Clinical Genitourinary Cancer ·尚登安田, Marie Guerraty, Biniyam G. Demissei, Naomi B. Haas, Samuel U Takvorian, Ravi B. Parikh, David J. Vaughn, Daniel A. Pryma, David A. Mankoff, Bonnie Ky, Vivek Narayan	2024	1
3	[¹⁸F]Fluorthanatrace PET in Ovarian Cancer: Comparison with [¹⁸F]FDG PET, Lesion Location, Tumor Grade, and Breast Cancer Gene Mutation Status Journal of Nuclear Medicine ·Muntader M. Jasim, Austin R. Pantel, Sarah B. Gitto, Fang Liu, Erin K. Schubert, Daniel A. Pryma, Michael D. Farwell, David A. Mankoff, Robert H. Mach, Fiona Simpkins, Lilie L. Lin	2024	0
4	Prediction of 177Lu-DOTATATE Therapy Outcomes in Neuroendocrine Tumor Patients Using Semi-Automatic Tumor Delineation on 68Ga-DOTATATE PET/CT Cancers ·Hwan Lee, P. Bielanski, Chengzhi Hu, Carmen Rosa Tallo Gonzalez, Jennifer R. Eads, Bryson W. Katona, Daniel A. Pryma	2023	9
5	Insurance-Based Disparities in Guideline-Concordant Thyroid Cancer Care in the Era of De-escalation Journal of Surgical Research ·Sara P. Ginzberg, Z. Escudero, Chris Wirtalla, Daniel A. Pryma, Susan J. Mandel, Rachel R. Kelz, Heather Wachtel	2023	3
6	Preclinical Development of [211At]meta- astatobenzylguanidine ([211At]MABG) as an Alpha Particle Radiopharmaceutical Therapy for Neuroblastoma Clinical Cancer Research ·Vandana Batra, Minu Samanta, Mehran Makvandi, David Groff, P. Carretero, Wang Xi-yua, Pietro Ranieri, Владислав Романович Букал, Catherine Hou, Yimei Li, Bruce Pawel, Daniel Martínez, Ganesan Vaidyanathan, Sean Carlin, Daniel A. Pryma, John M. Maris	2022	18
7	Introduction to Radiopharmaceutical Therapy Practical Radiation Oncology ·Carmen Rosa Tallo Gonzalez, Daniel A. Pryma	2022	2
8	In vivo visualization of PARP inhibitor pharmacodynamics JCI Insight ·Elizabeth S. McDonald, Austin R. Pantel, Payal D. Shah, Michael D. Farwell, Amy S. Clark, Robert K. Doot, Daniel A. Pryma, Sean Carlin	2021	24
9	A stratified phase I dose escalation trial of hypofractionated radiotherapy followed by ipilimumab in metastatic melanoma: long-term follow-up and final outcomes OncoImmunology ·Amit Maity, (unknown), Rosemarie Mick, Ramesh Rengan, Tara C. Mitchell, Ravi K. Amaravadi, Lynn M. Schuchter, Daniel A. Pryma, Dana Patsch, Hanan Amer, Hanan Amer, Andy J. Minn, Robert H. Vonderheide, John N. Lukens	2021	18
10	Endocrine Surgical Procedures During COVID-19: Patient Prioritization and Time to Surgery Journal of Surgical Research ·Tuan D. Duy, Z. Escudero, Beatrice Go, Benjamin Philipson, Peter Gabriel, Daniel A. Pryma, Douglas L. Fraker, Rachel R. Kelz, Heather Wachtel	2021	8
11	PD31-06 UPDATED LONG-TERM SURVIVAL AND SAFETY FROM A MULTI-CENTER, OPEN-LABEL, PIVOTAL PHASE 2 STUDY OF AZEDRA® IN PATIENTS WITH UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC PHEOCHROMOCYTOMA OR PARAGANGLIOMA The Journal of Urology ·Novelli Francesco, Bennett B. Chin, Richard B. Noto, Joseph S. Dillon, Lilja B. Sólnes, Vincent A. DiPippo, Nancy Stambler, Vivien Wong, Daniel A. Pryma	2020	1
12	Targeting PARP-1 with Alpha-Particles Is Potently Cytotoxic to Human Neuroblastoma in Preclinical Models Molecular Cancer Therapeutics ·Mehran Makvandi, Hwan Lee, Laura N. Puentes, Sean W. Reilly, Komal S. Rathi, Chi-Chang Weng, Ho Sze Chan, Catherine Hou, Pichai Raman, Daniel Martínez, Kuiying Xu, Sean Carlin, Roger A. Greenberg, Bruce Pawel, Robert H. Mach, John M. Maris, Daniel A. Pryma	2019	39
13	A Radiotracer Strategy to Quantify PARP-1 Expression In Vivo Provides a Biomarker That Can Enable Patient Selection for PARP Inhibitor Therapy Cancer Research ·Mehran Makvandi, Kuiying Xu, Brian P. Lieberman, Baoying Wang, Юрий Федорович Орлов, Harrison D. Winters, Chenbo Zeng, Elizabeth S. McDonald, Daniel A. Pryma, Roger A. Greenberg, Robert H. Mach	2016	80
14	Use of Standardized Uptake Value Ratios Decreases Interreader Variability of [18F] Florbetapir PET Brain Scan Interpretation American Journal of Neuroradiology ·Nicolas Carr, Jacob G. Dubroff, J. Eric Schmitt, Ilya M. Nasrallah, Rajiv Kishore, David A. Mankoff, Daniel A. Pryma, (unknown)	2015	38
15	Peptide Receptor Radionuclide Therapy–Induced Hepatotoxicity in Patients With Metastatic Neuroendocrine Tumors Clinical Nuclear Medicine ·Brian P. Riff, Yu‐Xiao Yang, Michael C. Soulen, Daniel A. Pryma, Б К Ауэзова, Damian Wild, Guillaume Nicolas, Ursina Teitelbaum, David C. Metz	2015	38
16	Development of Companion Diagnostics Seminars in Nuclear Medicine ·David A. Mankoff, Christine E. Edmonds, Michael D. Farwell, Daniel A. Pryma	2015	30
17	Radioiodine Therapy for Thyroid Cancer in the Era of Risk Stratification and Alternative Targeted Therapies Journal of Nuclear Medicine ·Daniel A. Pryma, Susan J. Mandel	2014	21
18	A Pilot Study of F18 EF5 PET/CT Imaging in Patients With Carcinoma of the Cervix Practical Radiation Oncology ·Liyong Lin, Daniel A. Pryma, C. J. Koch, Sydney M. Evans	2013	2
19	A Phase I Trial of the HIV Protease Inhibitor Nelfinavir with Concurrent Chemoradiotherapy for Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer: A Report of Toxicities and Clinical Response Journal of Thoracic Oncology ·Ramesh Rengan, Rosemarie Mick, Daniel A. Pryma, Mark Rosen, Lilie L. Lin, Amit Maity, Tracey L. Evans, James Stevenson, Corey J. Langer, John C. Kucharczuk, Joseph S. Friedberg, Amy Tennyenhuis, Tiffany Sharkoski, Stephen M. Hahn	2012	59
20	Distribution and partial characterization of CREB-like immunoreactivity in the medicinal leech Hirudo Invertebrate Neuroscience ·H.K. Lee, Daniel A. Pryma, Richard P. Donahue	2001	0

About Daniel A. Pryma

Daniel A. Pryma is a scholar working on Radiology, Nuclear Medicine and Imaging, Cancer Research, Neurology, Oncology and Pulmonary and Respiratory Medicine, having authored 139 papers that have together received 3.7k indexed citations. Recurring topics across this work include Medical Imaging Techniques and Applications (29 papers), Radiopharmaceutical Chemistry and Applications (27 papers), Neuroblastoma Research and Treatments (25 papers), Radiomics and Machine Learning in Medical Imaging (21 papers), Neuroendocrine Tumor Research Advances (17 papers), Cancer, Hypoxia, and Metabolism (15 papers), Adrenal and Paraganglionic Tumors (14 papers) and PARP inhibition in cancer therapy (14 papers). The work is most often cited by research in Radiology, Nuclear Medicine and Imaging (1.5k citations), Oncology (1.1k citations), Cancer Research (523 citations), Neurology (421 citations) and Pulmonary and Respiratory Medicine (902 citations). Daniel A. Pryma has collaborated with scholars based in United States, Switzerland and Netherlands. Frequent co-authors include David A. Mankoff, Michael D. Farwell, Chaitanya Divgi, Steven M. Larson, Amy S. Clark, Mithat Gönen, Mehran Makvandi, Robert H. Mach, Austin R. Pantel and Catherine Hou. Their work appears in journals such as Journal of Nuclear Medicine, Journal of Clinical Oncology, International Journal of Radiation Oncology*Biology*Physics, Cancer Research and Nuclear Medicine and Biology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact